Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.36 |
| ▸ | PTPRC | P08575 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.34 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27020293 | 0.88 | GAA (0.40) | KMT2AENPP2 | |
| SCHEMBL1916259 | 0.86 | PLA2G10 (0.37) | EPHX2NAMPTPTPRCOPRM1OPRL1 | |
| SCHEMBL1916264 | 0.86 | PLA2G10 (0.37) | EPHX2NAMPTPTPRCOPRM1OPRL1 | |
| SCHEMBL7215369 | 0.79 | THRB (0.39) | EPHX2CACNA1BKMT2A | |
| SCHEMBL7406437 | 0.72 | CYP3A4 (0.50) | CACNA1BKMT2AKLK5 | |
| SCHEMBL7406434 | 0.72 | CYP3A4 (0.50) | CACNA1BKMT2AKLK5 | |
| SCHEMBL6240853 | 0.71 | KMT2A (0.49) | KMT2AKLK5 | |
| SCHEMBL9367720 | 0.71 | KMT2A (0.43) | METAP1KMT2A | |
| SCHEMBL30492989 | 0.70 | NAMPT (0.43) | EPHX2NAMPT | |
| SCHEMBL6262070 | 0.70 | EPHX2 (0.47) | EPHX2NAMPTPTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016941-A1 | COMBINATION THERAPY | ANTABIO SAS (FR) | 2024-01-18 | — | — | US | disclosed |
| US-20240016941-A1 | COMBINATION THERAPY | ANTABIO SAS (FR) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016941-A1 | COMBINATION THERAPY | CFTR, ABCB11, SLC26A4 | EPHX2 3077/4885CACNA1B 896/4885NAMPT 2004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.